Sp920

MANAGEMENT OF INCIDENTALLY DETECTED PANCREATIC NEUROENDOCRINE TUMORS

Date
May 8, 2023
Explore related products in the following collection:

Society: AGA

This session is co-sponsored by the North American Neuroendocrine Tumor Society (NANETS). Clinically focused session focused on management of incidentally discovered neuroendocrine tumors, with a specific focus on the role of the gastroenterologist in this management. The session will have talks focused on incidentally discovered neuroendocrine tumors including gastroduodenal neuroendocrine tumors, pancreatic neuroendocrine tumors, and colorectal neuroendocrine tumors. Incidental identification of gastroenteropancreatic neuroendocrine tumors is becoming increasing common in gastroenterology practice, and therefore gastroenterologists need to understand how to manage these tumors when they are encountered.

Presenter

Speaker Image for Linda Lee
Brigham and Women's Hospital

Tracks

Related Products

Thumbnail for MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Thumbnail for INTRODUCTION
INTRODUCTION
SOCIETY: AGA
Thumbnail for PLACEHOLDER
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
Thumbnail for A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…